Delayed pyridine nucleotide reoxidation induced by the anticancer agent VM-26 as measured in vivo and in situ by NADH microfluorimetry.
D000818:Animals; D001921:Brain / Q000378:metabolism; D005260:Female; D005470:Fluorometry; D000860:Hypoxia / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D009243:NAD / Q000378:metabolism*; D010084:Oxidation-Reduction; D010101:Oxygen Consumption / Q000187:drug effects; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D051381:Rats; D012208:Rhabdomyosarcoma / Q000378:metabolism; D012513:Sarcoma, Experimental / Q000378:metabolism*; D013713:Teniposide / Q000494:pharmacology
D009243:NAD; D013713:Teniposide; D011034:Podophyllotoxin